Background
==========

The identification of chemical and physical agents potentially hazardous for human health is a great challenge involving a great deal of time and money, since inexpensive high-throughput assays are not yet available. In addition, research involving living animals conflicts with the personal beliefs of a large strata of the population.

Transgenic technology was proposed to address the issue of genotoxicity and toxicology \[[@B1]-[@B5]\]. We previously described transgenic mice that bear the human growth hormone (hGH) as a reporter gene whose expression is driven by the regulatory sequences of the heat shock protein 70 gene (*hsp70/hGH*mice) \[[@B4]\]. In the blood of these mice, high levels of hGH were specifically detected after administration of known toxic, non-genotoxic inorganic compounds, such as arsenic and cadmium. In addition, we showed that *hsp70/hGH*transgenic-derived primary cells, including hepatocytes, specifically release hGH in the culture medium after exposure to toxic inorganic compounds.

Cultured mammalian hepatocytes retaining differentiated hepatic functions would be greatly useful in toxicology. However, primary hepatocytes have a very limited life span and must be freshly derived from mice or even humans. Various attempts to use transformed hepatocyte cell lines or to genetically engineer primary hepatocytes for toxicological studies have been unsatisfactory, since they rapidly modify their repertoire of tissue-specific gene expression including metabolising enzymes \[[@B6]-[@B9]\]. In this regard, a major breakthrough came from the discovery that the liver-specific transgenic expression of a truncated form of the hepatocyte growth factor receptor (*cytoMET*) under the control of the α~1~-antitrypsin (*AT*) promoter reproducibly permits immortalization of untransformed and highly-differentiated hepatocyte cell lines (MMH) \[[@B10],[@B11]\].

Based on these considerations, we crossed *hps70/hGH*with *AT-cytoMET*mice, obtaining double transgenic mice and from them stable hepatocyte cell lines (MMH-GH). The results shown in the present paper indicate that these MMH-GH cell lines, which specifically expressed the reporter hGH gene after exposure to inorganic and organic compounds with known toxicity, may represent a useful tool in toxicological studies.

Results
=======

Several stable cell lines (MMH-GH1, MMH-GH2, MMH-GH5, MMH-GH9, MMH-GH10, MMH-GH11) were derived from liver explants of double transgenic 18 days post coitum embryos as described in the Methods section. As expected, all the 6 lines tested failed to grow in soft agar and to form tumors in nude mice (data not shown), in accordance with previous observations showing that *cytoMET*transgenic expression renders hepatocytes permissive for immortalization without cellular transformation \[[@B10]\].

To gather further evidence on the differentiated hepatic phenotype of these lines, we documented epithelial polarity and liver specific gene expression. Immunofluorescence analysis showed in Figure [1](#F1){ref-type="fig"} highlights the expression and the cellular localization of polarity markers such as ZO-1 and the epithelium-specific adhesion molecule E-cadherin in two different MMH-GH clones and as positive and negative controls, in a well polarized and previously described MMH line (MMHE14) and in a undifferentiated, non polarized and transformed MMH line (MMHE14/Myc) respectively. Both proteins are visible as a fine network on the membrane areas of cell-cell contact, indicating that the cells of both lines retain a simple epithelial polarity. Moreover, the staining for cytokeratins reveals an abundant network of these intermediate filaments, outlining the epithelial growth habit of the cells.

In order to explore their application in toxicological studies we analyzed by RT-PCR some key enzymes involved in the detoxifying machinery, highlighting a coherent pattern of gene expression. As shown in Figure [1b](#F1){ref-type="fig"}, liver-enriched transcription factors (HNFs), phase I (drug and carcinogen-activating), phase II (detoxifying) and gluconeogenesis supporting enzymes are expressed in MMH-GH lines; similar results were obtained at early (3) and late (23) passages after the first thawing.

Six independent clones of MMH-GH cells were then tested for their ability to respond to *in vitro*toxic stimulation. Cells were treated with NaAsO~2~and CdCl~2~at concentrations ranging from 10^-5^to 10^-4^M for 5 or 24 h (data not shown). These conditions were chosen according to results previously obtained with *hsp70/hGH*transgenic primary hepatocytes \[[@B4]\]. The MMH-GH5 clone, showing a basal level of secreted hGH below the detection limit and a high response to treatments, was selected for further studies.

The hGH secretion and the cellular viability of MMH-GH5 and PHGH cells from *hsp70/hGH*mice in response to the toxic inorganic compounds NaAsO~2~and CdCl~2~were evaluated (Fig [2](#F2){ref-type="fig"}). While the response to NaAsO~2~was comparable at each concentration tested in both cell lines, after exposure to CdCl~2~we observed differing behaviour in the two models. PHGH showed an inverse correlation between cadmium concentration and hGH release while MMH-GH5 showed a linear response (panel A). This result is based on the different viability of the two cell populations (panel B). Notably, the MMH-GH5 cells showed a higher cell viability after exposure to high doses of toxic inorganic compounds, which results in a dose-response linearity of the hGH release.

To test whether primary and immortalized hepatocytes were able to respond also to toxic organic compounds, we tested four known toxic agents: Benzo(a)pyrene (BaP), considered mainly a genotoxic agent, PentaChloroPhenol (PCP), TetraChloroHydroQuinone (TCHQ, the major *in vivo*metabolite of PCP) and 1-Chloro-2,4-DiNitro-Benzene (CDNB). PHGH and MMH-GH5 cells were exposed to two different concentrations of these compounds for 1 and 5 hours. hGH levels were measured in the medium either immediately after the treatment or after 24 hours of recovery with control medium.

As shown in [Additional file: 1](#S1){ref-type="supplementary-material"}, PHGH cells, while capable of responding to TCHQ and CDNB, did not show elevated hGH levels in response to BaP and PCP, due to the cytotoxicity of these compounds, as indicated by the low percentage of residual viable cells. On the other hand, MMH-GH5, showing a higher viability, responded to all four compounds, thus providing a suitable cell-based assay also for these compounds. It is possible that this different behaviour is due to the fact that stable cell lines better adapt to culture conditions than primary cells and are more resistant to toxic insults.

Discussion
==========

In spite of many assays developed in lower organisms, mammalian hepatocytes still represent a compulsory step in the evaluation of toxic compounds because they carry out modifications leading to the production of various metabolites, which are the ultimate causes of toxicity \[[@B12],[@B13]\]. However, their use so far has been restricted to two models, primary cultured hepatocytes and hepatoma cell lines both of which have several drawbacks. Primary hepatocytes, used as cultures or tissue slices must be continuously derived from living animals or even humans, their functional activities decline rapidly after a few days under conventional culture conditions and their response is dependent on many variables, while hepatoma cell lines lose features of the hepatocyte, such as drug- and toxic-activating enzymes \[[@B13],[@B14]\]. Engineered immortalized human cell lines have also been developed, with different results \[[@B6]-[@B9]\].

To overcome these limitations, we have developed new bi-transgenic immortalized hepatocyte cell lines, named MMH-GH. As detailed in previous reports, the transgenic expression of *cytoMET*, a truncated form of the *c-MET*oncogene, permits the immortalization of hepatocytes (MMH) that retain and perform *in vitro*complex liver functions \[[@B10]\]. In the work reported here, we report that these cells represent a novel tool that can be used in toxicology studies. As shown above, each inorganic and organic toxic compound tested so far caused specific hGH release, albeit with different kinetics in agreement with the results obtained by Ait-Aissa et al \[[@B15]\], who showed that hsp70 induction is different depending on the classes of compounds. Notably, for the correct interpretation of these tests, both hGH levels and cellular viability parameters must be taken into account.

Conclusions
===========

We believe that MMH-GH cell lines provide a cheap, reproducible, rapid, reliable and ethically acceptable tool that has several innovative features. The major advantages are: 1 -- the use of stable cell lines allows a drastic reduction of animals sacrificed for toxicology research; 2 -- the cells are of the histotype most widely used for toxicological studies; 3 -- the cells retain in culture the morphology, phenotype and functions mimicking hepatocytes in the living animal; 4 -- this assay, based on clonal cell populations, has with respect to primary cultures greater potentiality for standardization; 5 -- the presence of the reporter gene under the control of a stress-responsive promoter allows us to perform a quantitative, rapid and low-cost assay able to detect early cell damage.

The fact that our detection system is able to identify hsp70 promoter induction at low doses (\[[@B5]\]; Figure [2](#F2){ref-type="fig"} and [Additional file: 1](#S1){ref-type="supplementary-material"}) is an advantage over traditional hepatocyte culture systems which rely upon viability as the key end point. Standardization of an *in vitro*assay based on MMH-GH5 cells will allow a significant reduction in the number of animals sacrificed, a very sensitive issue shared by both public Institutions and pharmaceutical industries \[[@B16],[@B17]\]. Several clones can be derived from a small number of transgenic mice and can be used for a indefinite number of tests. Moreover, cellular clones with the best features may be selected, different species (rats or fish \[[@B18]\]) could be engineered, different promoters and different reporter genes could be used, as already suggested \[[@B5]\], to further exploit the potentiality of this approach. In addition, promoter elements for stress proteins of hsp genes with more restricted responses to stress could be applicable for further refining this system. Finally, by thoroughly investigating the metabolic pathways regulated by truncated *cytoMet*, human immortalized hepatocytes maintaining features of differentiated liver cells could be produced and used in toxicology studies.

Methods
=======

Chemicals
---------

NaAsO~2~and CdCl~2~were purchased from Merck (Darmstad, Germany); B(a)P, PCP, TCHQ, CDNB, were purchased from SIGMA (St Louis, MO). All the cell culture reagents were from SIGMA and all the plastic material from Falcon (San Jose, CA).

Isolation of primary hepatocytes
--------------------------------

The day before the treatment, the parenchymal component of liver cells was isolated as previously described \[[@B4]\] and seeded in 24 well plates in William\'s E medium supplemented with 10% heat inactivated FCS and Pen/Strep. After 2 hours the medium was replaced to remove floating cells.

Derivation of hepatic stable cell lines and cell culture
--------------------------------------------------------

The experimental protocol was approved by the Scientific Committee of the Istituto di Tecnologie Biomediche, CNR. The production and characterization of the two transgenic strains (*hsp70/hGH*and *cytoME*T) used in the present study have been previously described \[[@B4],[@B10],[@B11]\]. Homozygous mice from the two strains were crossed to generate double heterozygous animals. Animal care and sacrifice were performed according to the EU guidelines \[[@B19]\] and hepatocytes were obtained and cultured as previously described \[[@B4],[@B10]\]. Briefly, livers from 18 dpc bi-transgenic foetuses were dissected, mechanically dissociated and plated at high density on collagen I (Sigma) coated Nunc Petri dishes in RPMI 1640 containing 10% FCS, 50 ng/ml EGF, 30 ng/ml IGF II, 10 micrograms/ml insulin (Boehringer Mannheim) and antibiotics. The cultures were maintained without transfer for several weeks. Individual epithelial islands were slowly expanded in collagen I-coated dishes of increasing size, and frozen after around 25 cell generations. Passages are calculated from initial thawing.

The day before the treatment with chemicals, MMH-GH cells were seeded at 80% confluence in 12 well plates pre-coated with collagen in complete medium. The treatments were performed in the same medium without FCS.

Immunofluorescence
------------------

For indirect immunofluorescence staining, cells were grown on collagen I-coated glass cover slips, fixed by immersion in methanol/acetone (3:7, vol/vol) for 15 min at 20°C and then air dried. Coverslips were then incubated for 1 h at room temperature in humidified atmosphere with the primary antibody. After three washes with PBS, the coverslips were incubated with the secondary fluorochrome-conjugated antibody diluted in PBS plus 3% BSA, washed repeatedly with PBS, and mounted with 70% glycerol in PBS. The samples were analyzed under phase contrast and appropriate fluorescent light.

The antibodies were obtained and used as follows: mouse monoclonal anti-pan-Cytocheratin antibody from Sigma Chemical Co., diluted 1/100; rat monoclonal anti-zonula occludens (ZO)-1 antibody from Zymed diluted 1/100; mouse monoclonal anti-E-Cadherin antibody from Signal Transduction Laboratories (Lexington, KY), diluted 1/100; sheep anti-mouse Ig FITC linked whole antibody from Amersham International, used 1/100; rabbit polyclonal anti-rat IgG FITC conjugated antibody from Sigma Chemical Co., diluted 1/100.

The cell lines used as positive and negative controls of epithelial polarity were MMH line E14 described in \[[@B10]\] and the same cell line transduced with activated, transforming form of cMyc E14/Myc (unpublished) respectively.

RNA analysis by RT-PCR
----------------------

Single-stranded cDNAs were obtained from reverse transcription of 1 microgram of total RNA extracted from MMH, MMH-GH5 and MMH-GH9 cells and wild type liver using oligo(dT)-primers and M-MLV reverse transcriptase (Promega, Madison, WI), in a final reaction volume of 25 microliters according to the manufacturer\'s conditions. The cDNAs were amplified by PCR according to the standard protocol using forward and reverse specific primers. The PCR products were electrophoresed on 1% agarose gels and then transferred to Quiabrene Nylon membrane (Quiagen, Germany) for hybridization. Blots were probed with internal ^32^P-labeled oligonucleotides. The amplified genes \[[@B20]-[@B23]\], the primers used for amplification and the internal probes are listed in [Additional file: 2](#S2){ref-type="supplementary-material"}, together with their NCBI accession numbers.

In vitro treatments
-------------------

All the stock solutions were dissolved at the final concentration in culture medium without FCS. NaAsO~2~, CdCl~2~were dissolved in H~2~O at the concentration of 10^-2^M as stock solution and then diluted to 10^-5^(dose 1), 5 × 10^-5^M (dose 2) and 10^-4^M (dose 3).

B(a)P, PCP, TCHQ and CDNB were dissolved according to the manufacturer\'s instructions in different solvents at 5 mM concentration as stock solution and then diluted in culture medium. B(a)P was administered at 10 and 50 microM, CDNB at 5 and 50 microM, while PCP and TCHQ were administered at 50 and 100 microM concentrations. These concentrations were chosen on the basis of data previously reported by Ait-Aissa et al \[[@B15]\].

Each treatment was carried out for 1 and 5 hours, then the supernatant was removed, frozen at -20° and replaced with fresh medium without FCS for another 24 hours. Every treatment was carried out in duplicate and every experiment was repeated at least 5 times. In every experiment control treatments were included in which cells received only culture medium.

Viability
---------

Cell viability was determined at the end of treatments by Trypan blue dye exclusion method, as previously described \[[@B4]\].

Determination of hGH release
----------------------------

The concentration of hGH released in the supernatant after the treatments was determined as previously described \[[@B4]\] with an ELISA test, (hGH ELISA detection kit, Roche). Each determination was carried out in duplicate. The results were expressed as pg of hGH/10^6^cells.
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Figures and Tables
==================

![**MMH-GHs maintain a highly-differentiated phenotype at morphological and molecular levels**. **Panel A**shows the immunofluorescence analysis of E-Cadherin, ZO-1 and cytokeratins expression and localization in MMH-GH clones, in a well polarized MMHline (MMHE14) and in a transformed, undifferentiated MMH line(MMH/Myc). Phase-contrast images and microphotographs of E-Cadherin immunostaining represent the same fields. **Panel B**shows the RT-PCR analysis of RNA extracted from an MMH clone, from adult liver as control and from two different MMH-GH cell lines (MMH-GH5 and MMH-GH9). The amplified fragments are shown in the left side of the panel, while in the right side the Southern Blot analysis of the same amplified sequences performed with oligonucleotides used as internal probes is shown. Normalization of RT-PCR was obtained by amplification of beta-actin cDNA. The genes considered are: liver-enriched transcription factors (HNF1a, HNF1b, HNF4), drug and carcinogen-activating and -detoxifying enzymes (Glutamine Synthethase, GLNS; UDP-glucuronosyl-transferase, UDP-GT; Cytochrome P450 1A1, Cyp1A1; Epoxide hydrolase, Eph) and gluconeogenesis supporting enzymes (Lactate dehydrogenase, LDH; Glutamate-oxaloacetate-transaminase 1, Got1; Glutamate-oxaloacetate-transaminase 2, Got2). Oligonucleotides used as forward and reverse primers for PCR and as internal probes in Southern Blot analysis are listed in [Additional file: 2](#S2){ref-type="supplementary-material"}, together with the NCBI accession numbers of the sequences from which they were derived.](1472-6750-4-5-1){#F1}

![**MMH-GH5 and PHGH response to toxic inorganic compoundsPanel A**. Results represent Mean ± SE of hGH levels secreted by PHGH and MMH-GH5 cells after a 5 hour treatment with different concentrations of NaAsO~2~(As1: 10^-5^M, As2: 5 × 10^-4^M, As3: 10^-4^M) and CdCl~2~(Cd1: 10^-5^M, Cd2: 5 × 10^-4^M, Cd3: 10^-4^M). **Panel B**. Mean ± SE of viability of PHGH and MMH-GH5 at the indicated treatment conditions as determined by the Trypan blue dye exclusion method. These results were obtained from 6 independent experiments with treatments carried out in triplicate.](1472-6750-4-5-2){#F2}
